Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - concentrated antigens of dichelobacter nodosus; light liquid paraffin; thiomersal - misc. vaccines or anti sera - concentrated antigens of dichelobacter nodosus vaccine-antigen/antibody active 100.0 ug/ml; light liquid paraffin ungrouped other 600.0 ul/ml; thiomersal mercury other 0.05 mg/ml - immunotherapy - lamb | sheep | ewe | hogget | lamb | ovine | ram | weaner | wether - footrot - dichelobacter nodosus

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - estriol, quantity: 1 mg - tablet, uncoated - excipient ingredients: amylopectin; potato starch; lactose monohydrate; magnesium stearate - short-term treatment of menopausal syndrome. review the need for continuation of treatment after 6 months treatment, taking into account the risk-benefit ratio for the individual user at that moment (including cardiovascular disease and breast cancer, refer to clinical trials and precautions). ovestin tablets should only be continued for as long as the benefit outweighs the risks.

Australia - English - Department of Health (Therapeutic Goods Administration)

eisai australia pty ltd - perampanel hemisesquihydrate, quantity: 10.4 mg (equivalent: perampanel, qty 10 mg) - tablet, film coated - excipient ingredients: purified talc; iron oxide yellow; hypromellose; lactose monohydrate; povidone; indigo carmine aluminium lake; macrogol 8000; titanium dioxide; microcrystalline cellulose; magnesium stearate - fycompa is indicated for the adjunctive treatment of:,1) partial-onset seizures (pos) with or without secondarily generalised seizures in patients from 4 years of age with epilepsy.,2) primary generalised tonic-clonic seizures (pgtcs) in patients from 7 years of age with idiopathic generalised epilepsy.

Australia - English - Department of Health (Therapeutic Goods Administration)

eisai australia pty ltd - perampanel hemisesquihydrate, quantity: 12.5 mg (equivalent: perampanel, qty 12 mg) - tablet, film coated - excipient ingredients: hypromellose; povidone; microcrystalline cellulose; indigo carmine aluminium lake; purified talc; magnesium stearate; lactose monohydrate; macrogol 8000; titanium dioxide - fycompa is indicated for the adjunctive treatment of:,1) partial-onset seizures (pos) with or without secondarily generalised seizures in patients from 4 years of age with epilepsy.,2) primary generalised tonic-clonic seizures (pgtcs) in patients from 7 years of age with idiopathic generalised epilepsy.

Australia - English - Department of Health (Therapeutic Goods Administration)

eisai australia pty ltd - perampanel hemisesquihydrate, quantity: 2.1 mg (equivalent: perampanel, qty 2 mg) - tablet, film coated - excipient ingredients: purified talc; iron oxide red; iron oxide yellow; titanium dioxide; macrogol 8000; hypromellose; lactose monohydrate; magnesium stearate; povidone - fycompa is indicated for the adjunctive treatment of:,1) partial-onset seizures (pos) with or without secondarily generalised seizures in patients from 4 years of age with epilepsy.,2) primary generalised tonic-clonic seizures (pgtcs) in patients from 7 years of age with idiopathic generalised epilepsy.

Australia - English - Department of Health (Therapeutic Goods Administration)

eisai australia pty ltd - perampanel hemisesquihydrate, quantity: 4.2 mg (equivalent: perampanel, qty 4 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; titanium dioxide; hypromellose; povidone; purified talc; iron oxide red; macrogol 8000 - fycompa is indicated for the adjunctive treatment of:,1) partial-onset seizures (pos) with or without secondarily generalised seizures in patients from 4 years of age with epilepsy.,2) primary generalised tonic-clonic seizures (pgtcs) in patients from 7 years of age with idiopathic generalised epilepsy.

Australia - English - Department of Health (Therapeutic Goods Administration)

eisai australia pty ltd - perampanel hemisesquihydrate, quantity: 6.2 mg (equivalent: perampanel, qty 6 mg) - tablet, film coated - excipient ingredients: titanium dioxide; macrogol 8000; hypromellose; purified talc; lactose monohydrate; microcrystalline cellulose; iron oxide red; magnesium stearate; povidone - fycompa is indicated for the adjunctive treatment of:,1) partial-onset seizures (pos) with or without secondarily generalised seizures in patients from 4 years of age with epilepsy.,2) primary generalised tonic-clonic seizures (pgtcs) in patients from 7 years of age with idiopathic generalised epilepsy.

Australia - English - Department of Health (Therapeutic Goods Administration)

eisai australia pty ltd - perampanel hemisesquihydrate, quantity: 8.3 mg (equivalent: perampanel, qty 8 mg) - tablet, film coated - excipient ingredients: purified talc; macrogol 8000; iron oxide red; iron oxide black; povidone; hypromellose; magnesium stearate; microcrystalline cellulose; lactose monohydrate; titanium dioxide - fycompa is indicated for the adjunctive treatment of:,1) partial-onset seizures (pos) with or without secondarily generalised seizures in patients from 4 years of age with epilepsy.,2) primary generalised tonic-clonic seizures (pgtcs) in patients from 7 years of age with idiopathic generalised epilepsy.

Australia - English - Department of Health (Therapeutic Goods Administration)

macquarie medical systems pty ltd - 16837 - compression unit, sequential - sequential venous compression system: compression/non-compression non-invansive device for the lower part of the body (legs, thighs and abdomen) to reproduce and / or stimulate the natural physiological pulsations and the physical sheer stress forces.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 20 microgram; drospirenone, quantity: 3 mg - tablet, uncoated - excipient ingredients: magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; purified talc; microcrystalline cellulose - yaz is indicated for use as: - an oral contraceptive. - treatment of moderate acne vulgaris in women who seek oral contraception - treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of yaz for pmdd was not assessed beyond 3 cycles. yaz has not been evaluated for treatment of pms (premenstrual syndrome), see clinical trials.